News

May 24, 2020

POINT Biopharma Announces Manufacturing Leadership and Search for US manufacturing site

POINT Biopharma Inc. today announced the appointment of Todd Hockemeyer as Executive Vice President of US Manufacturing Operations. An industrial engineer, with operations and manufacturing expertise spanning over 25 years, Hockemeyer...

May 12, 2020

POINT Biopharma Announces Phase 3 Prostate Cancer Trial

POINT Biopharma Inc. is pleased to announce the selection of PSI CRO to manage its phase 3 clinical study of PNT2002, a 177Lu-PSMA radiotherapeutic for the treatment of metastatic castrate-resistant prostate cancer.“PSI CRO is a leading...

April 7, 2020

POINT Biopharma Announces Global Prostate Oncology Therapeutic Board of Advisors

POINT Biopharma Inc. is pleased to announce theformation of its global prostate oncology therapeutic advisory board.The Board, comprised of leading global experts in scientific discovery and clinical leadership, will provide guidance, p...

March 10, 2020

POINT Biopharma and SCINTOMICS Announce License Agreement

POINT Biopharma Inc. today announced that it has entered into an agreement with SCINTOMICS GmbH for the exclusive use and development of a family of more than seventy patented next generation PSMA radioligands for targeted radiothera...

February 25, 2020

Point Biopharma launches with Radiopharmaceutical development focus

POINT Biopharma, a newly formed pharmaceutical company, is combining a seasoned management team with strategic partnerships in radio-isotope supply, manufacturing technology and novel direct to patient targeting to revolutionize radi...